You are here

CAR-T

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Endpoints

Flag link:

Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date

Bristol-Myers' CAR-T gets priority review, mid-August PDUFA date

Fierce Biotech

Bristol-Myers Squibb

lisocabtagene maraleucel

priority review

Flag link:

Gilead closes in on second CAR-T approval in US

Gilead closes in on second CAR-T approval in US

Pharmaforum

Gilead Sciences

mantle cell lymphoma

Flag link:

CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells

CAR-T tackles multiple myeloma by using the target CD229 to kill cancer stem cells

Fierce Biotech

Multiple Myeloma

Flag link:

Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial

Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial

Xconomy

Scripps Research Institute

Flag link:

MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner

MD Anderson emerges with strong evidence for natural killer cell therapy, and Takeda looks like a winner

Endpoints

natural killer cell therapy

Flag link:

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

Adaptimmune and Astellas to Co-Develop Allogenic CAR-T and TCR T-Cell Therapies

BioSpace

drug development

Flag link:

Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology

Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology

Endpoints

immuno-oncology

Flag link:

Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?

Docs are excited about CAR-T, BTK drugs, survey finds. How can pharma best promote them?

Fierce Pharma

Multiple Myeloma

Flag link:

Bristol-Myers unloads old-school plant as it readies for CAR-T future

Bristol-Myers unloads old-school plant as it readies for CAR-T future

Fierce Pharma

Bristol-Myers Squibb

Flag link:

3 trends in biotech to watch in 2020

3 trends in biotech to watch in 2020

Stat

Flag link:

Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles

Pharma's gene and cell therapy ambitions will kick into high gear in 2020—despite some major hurdles

Fierce Pharma

drug manufacturing

Bristol-Myers Squibb

Sarepta Therapeutics

Gilead Sciences

Flag link:

Anixa delays CAR-T trial in bid to boost efficacy

Anixa delays CAR-T trial in bid to boost efficacy

Fierce Biotech

Anixa Biosciences

Flag link:

Gilead's Kite files for FDA approval of second CAR-T therapy

Gilead's Kite files for FDA approval of second CAR-T therapy

Fierce Biotech

Gilead Sciences

mantle cell lymphoma

Flag link:

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Biopharma Dive

drug manufacturing

Flag link:

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Pharmaceutical Business Review

Flag link:

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

Fierce Pharma

Gilead Sciences

refractory large B-cell lymphoma

Flag link:

2 Small-Cap Biotechs That Soared Last Week

2 Small-Cap Biotechs That Soared Last Week

Motley Fool

Magenta Therapeutics

Molecular Templates

Flag link:

Celgene posts pivotal CAR-T data ahead of FDA filing

Celgene posts pivotal CAR-T data ahead of FDA filing

Fierce Biotech

Flag link:

CAR-T cells as 'bait' show promise in autoimmune disease

CAR-T cells as 'bait' show promise in autoimmune disease

Fierce Biotech

autoimmune disease

Flag link:

Pages